240 related articles for article (PubMed ID: 36987427)
1. ROS-responsive Galactosylated-nanoparticles with Doxorubicin Entrapment for Triple Negative Breast Cancer Therapy.
Zhou J; Li K; Zang X; Xie Y; Song J; Chen X
Int J Nanomedicine; 2023; 18():1381-1397. PubMed ID: 36987427
[TBL] [Abstract][Full Text] [Related]
2. Sequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition.
Fan J; Liu B; Long Y; Wang Z; Tong C; Wang W; You P; Liu X
Acta Biomater; 2020 Sep; 113():554-569. PubMed ID: 32569637
[TBL] [Abstract][Full Text] [Related]
3. Multifunctional Theranostic Nanoparticles for Enhanced Tumor Targeted Imaging and Synergistic FUS/Chemotherapy on Murine 4T1 Breast Cancer Cell.
Kang Z; Yang M; Feng X; Liao H; Zhang Z; Du Y
Int J Nanomedicine; 2022; 17():2165-2187. PubMed ID: 35592098
[TBL] [Abstract][Full Text] [Related]
4. Fenton-reaction-stimulative nanoparticles decorated with a reactive-oxygen-species (ROS)-responsive molecular switch for ROS amplification and triple negative breast cancer therapy.
Zhang J; Zuo T; Liang X; Xu Y; Yang Y; Fang T; Li J; Chen D; Shen Q
J Mater Chem B; 2019 Dec; 7(45):7141-7151. PubMed ID: 31663577
[TBL] [Abstract][Full Text] [Related]
5. Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy.
Son S; Shin S; Rao NV; Um W; Jeon J; Ko H; Deepagan VG; Kwon S; Lee JY; Park JH
Int J Biol Macromol; 2018 Apr; 110():406-415. PubMed ID: 29055700
[TBL] [Abstract][Full Text] [Related]
6. Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan-based nanoparticles.
Cheng B; Gao F; Maissy E; Xu P
Acta Biomater; 2019 Jan; 84():378-390. PubMed ID: 30528604
[TBL] [Abstract][Full Text] [Related]
7. Peptide mediated active targeting and intelligent particle size reduction-mediated enhanced penetrating of fabricated nanoparticles for triple-negative breast cancer treatment.
Hu G; Chun X; Wang Y; He Q; Gao H
Oncotarget; 2015 Dec; 6(38):41258-74. PubMed ID: 26517810
[TBL] [Abstract][Full Text] [Related]
8. CD44-specific nanoparticles for redox-triggered reactive oxygen species production and doxorubicin release.
Lin CW; Lu KY; Wang SY; Sung HW; Mi FL
Acta Biomater; 2016 Apr; 35():280-92. PubMed ID: 26853764
[TBL] [Abstract][Full Text] [Related]
9. Nitric oxide-releasing nanoparticles improve doxorubicin anticancer activity.
Alimoradi H; Greish K; Barzegar-Fallah A; Alshaibani L; Pittalà V
Int J Nanomedicine; 2018; 13():7771-7787. PubMed ID: 30538458
[TBL] [Abstract][Full Text] [Related]
10. ROS-responsive liposomes with NIR light-triggered doxorubicin release for combinatorial therapy of breast cancer.
Yi H; Lu W; Liu F; Zhang G; Xie F; Liu W; Wang L; Zhou W; Cheng Z
J Nanobiotechnology; 2021 May; 19(1):134. PubMed ID: 33975609
[TBL] [Abstract][Full Text] [Related]
11. A dual-sensitive nanoparticle-mediated deepening synergistic therapy strategy involving DNA damage and ICD stimuli to treat triple-negative breast cancer.
Liu S; Kong X; Fang Y; He Z; Wu H; Ji J; Yang X; Ye L; Zhai G
Biomater Sci; 2023 Sep; 11(18):6325-6341. PubMed ID: 37555273
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel mechanism for reversal of doxorubicin-induced chemotherapy resistance by TXNIP in triple-negative breast cancer via promoting reactive oxygen-mediated DNA damage.
Chen Y; Feng X; Yuan Y; Jiang J; Zhang P; Zhang B
Cell Death Dis; 2022 Apr; 13(4):338. PubMed ID: 35414060
[TBL] [Abstract][Full Text] [Related]
13. ROS triggered cleavage of thioketal moiety to dissociate prodrug nanoparticles for chemotherapy.
Pan Q; Deng X; Gao W; Chang J; Pu Y; He B
Colloids Surf B Biointerfaces; 2020 Oct; 194():111223. PubMed ID: 32615519
[TBL] [Abstract][Full Text] [Related]
14. Tumor-Associated Macrophage-Mediated Targeted Therapy of Triple-Negative Breast Cancer.
Niu M; Valdes S; Naguib YW; Hursting SD; Cui Z
Mol Pharm; 2016 Jun; 13(6):1833-42. PubMed ID: 27074028
[TBL] [Abstract][Full Text] [Related]
15. A pH-Sensitive Prodrug Nanocarrier Based on Diosgenin for Doxorubicin Delivery to Efficiently Inhibit Tumor Metastasis.
Wei Z; Wang H; Xin G; Zeng Z; Li S; Ming Y; Zhang X; Xing Z; Li L; Li Y; Zhang B; Zhang J; Niu H; Huang W
Int J Nanomedicine; 2020; 15():6545-6560. PubMed ID: 32943867
[TBL] [Abstract][Full Text] [Related]
16. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
17. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
[TBL] [Abstract][Full Text] [Related]
18. Targeted polymeric nanoparticles for drug delivery to hypoxic, triple-negative breast tumors.
Mamnoon B; Loganathan J; Confeld MI; De Fonseka N; Feng L; Froberg J; Choi Y; Tuvin DM; Sathish V; Mallik S
ACS Appl Bio Mater; 2021 Feb; 4(2):1450-1460. PubMed ID: 33954285
[TBL] [Abstract][Full Text] [Related]
19. Nano-delivery vehicle based on chlorin E6, photodynamic therapy, doxorubicin chemotherapy provides targeted treatment of HER-2 negative, ανβ3-positive breast cancer.
He Z; Jiang H; Zhang X; Zhang H; Cui Z; Sun L; Li H; Qian J; Ma J; Huang J
Pharmacol Res; 2020 Oct; 160():105184. PubMed ID: 32946931
[TBL] [Abstract][Full Text] [Related]
20. Polymeric graphene oxide nanoparticles loaded with doxorubicin for combined photothermal and chemotherapy in triple negative breast cancer.
Itoo AM; Paul M; Ghosh B; Biswas S
Biomater Adv; 2023 Oct; 153():213550. PubMed ID: 37437383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
